Skip to content

Researchers elevate brain protein to allay symptoms of Alzheimer’s in animal model.

Alzheimer’s disease is characterized by the degeneration of neurons in the hippocampus and cortex, and the appearance of neuritic plaques and neurofibrillary tangles.  Although the precise cause of Alzheimer’s disease remains unclear, and is in fact most likely from multiple etiologies.  Over the past several years, a consensus has emerged that a cocktail of drugs influencing multiple mechanisms may be required to effectively treat Alzheimer’s disease, however, this has yet to be validated.  Now, a study from researchers at the Salk Institute shows that boosting levels of a specific protein in the brain alleviates hallmark features of Alzheimer’s disease in a mouse model of the disorder.  The team state that their findings suggest neuregulin-1 has broad therapeutic potential, and shows that it promotes metabolism of the brain plaques that are characteristic of Alzheimer’s disease.  The opensource study is published in the journal Scientific Reports.

Previously studies show that treating cells with neuregulin-1 dampens levels of amyloid precursor protein, a molecule that generates amyloid beta, whose aggregates form plaques in the brains of Alzheimer’s patients. Other studies suggest that neuregulin-1 could protect neurons from damage caused by blockage of blood flow.  The current study tests this hypothesis by raising the levels of one of two forms of neuregulin-1 in the hippocampus, an area of the brain responsible for learning and memory.

The current study utilises a mouse model of Alzheimer’s disease to show that both forms of the protein seemed to improve performance on a test of spatial memory in the models.  Results show that the levels of cellular markers of disease, including the levels of amyloid beta and plaques, were noticeably lower in mice with more neuregulin-1 compared to controls.  Data findings show that neuregulin-1 breaks up plaques by raising levels of an enzyme called neprilysin, shown to degrade amyloid-beta.

The group state that a neuregulin-1 treatment is not available on the market, though it is being explored in clinical trials as a potential treatment for chronic heart failure and Parkinson’s disease. They go on to add that one advantage of neuregulin-1 as a potential drug is that it can cross the blood-brain barrier, which means that it could be administered noninvasively even though the efficiency is not clear.  They note that other research suggests too much of the protein impairs brain function.

The researchers state that they developed a small molecule which can raise levels of existing neuregulin-1, rather than administering it directly, and are testing it in cells. They explain that this alternative therapy could be a better way to prevent plaques from forming because small molecules more readily cross the blood-brain barrier.

The team surmise that their results suggest NRG1 provides beneficial effects in candidate neuropathologic substrates of Alzheimer’s disease and, therefore, is a potential target for the treatment of Alzheimer’s disease.  For the future, the researchers are testing neuregulin-1’s affects across other models.

Source: The Salk Institute For Biological Studies


In a mouse model of Alzheimer's disease, Salk Institute researchers show that raising levels of neuregulin-1 (right) lowers a marker of disease pathology in a part of the brain that controls memory compared with controls (left).  Credit: Salk Institute.
In a mouse model of Alzheimer’s disease, Salk Institute researchers show that raising levels of neuregulin-1 (right) lowers a marker of disease pathology in a part of the brain that controls memory compared with controls (left). Credit: Salk Institute.

Healthinnovations View All

Michelle Petersen is the founder of Healthinnovations, having worked in the health and science industry for over 21 years, which includes tenure within the NHS and Oxford University. Healthinnovations is a publication that has reported on, influenced, and researched current and future innovations in health for the past decade.

Michelle has been picked up as an expert writer for Informa publisher’s Clinical Trials community, as well as being listed as a blog source by the world’s leading medical journals, including the acclaimed Nature-Springer journal series.

Healthinnovations is currently indexed by the trusted Altmetric and PlumX metrics systems, respectively, as a blog source for published research globally. Healthinnovations is also featured in the world-renowned BioPortfolio,, the life science, pharmaceutical and healthcare portal.

Most recently the Texas A&M University covered The Top 10 Healthinnovations series on their site with distinguished Professor Stephen Maren calling the inclusion of himself and his team on the list a reflection of “the hard work and dedication of my students and trainees”.

Michelle Petersen’s copy was used in the highly successful marketing campaign for the mega-hit film ‘Jumanji: The Next Level, starring Jack Black, Karen Gilian, Kevin Hart and Dwayne ‘The Rock’ Johnson. Michelle Petersen’s copywriting was part of the film’s coverage by the Republic TV network. Republic TV is the most-watched English language TV channel in India since its inception in 2017.

An avid campaigner in the fight against child sex abuse and trafficking, Michelle is a passionate humanist striving for a better quality of life for all humans by helping to provide traction for new technologies and techniques within healthcare.

One thought on “Researchers elevate brain protein to allay symptoms of Alzheimer’s in animal model. Leave a comment

Leave a Reply

Translate »